The high-risk patient with heart failure with reduced ejection fraction: Treatment options and challenges

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 4, 2013, Pages 509-518

  Bartos, J A ^a   Francis, G S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALISKIREN; ALPHA ADRENERGIC RECEPTOR; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; EPLERENONE; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; METOPROLOL SUCCINATE; MILRINONE; NITROPRUSSIDE SODIUM; OLMESARTAN; SPIRONOLACTONE; TROPONIN; URIC ACID; VASODILATOR AGENT;

ACUTE HEART FAILURE; AGED; ASSISTED CIRCULATION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DYSPNEA; ECHOCARDIOGRAPHY; ENTEROPATHY; EOSINOPHILIA; GYNECOMASTIA; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT BUNDLE BRANCH BLOCK; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MALE; MEDICAL HISTORY; MITRAL VALVE REGURGITATION; PRIORITY JOURNAL; QRS COMPLEX; REVIEW; RISK ASSESSMENT; SEPTIC SHOCK; SYSTOLIC HEART FAILURE; TACHYCARDIA; TRICUSPID VALVE REGURGITATION; URIC ACID BLOOD LEVEL; VASODILATATION; WEIGHT GAIN;

BIOMARKERS, PHARMACOLOGICAL; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; CARDIOTONIC AGENTS; DISEASE MANAGEMENT; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RISK FACTORS; STROKE VOLUME; VASODILATOR AGENTS;

EID: 84884501580     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.137     Document Type: Review

References (70)

1. Go, A.S. et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127, e6-e245 (2013).
2. Rose, E.A. et al.; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N. Engl. J. Med. 345, 1435-1443 (2001).
3. Levy, W.C. et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113, 1424-1433 (2006). (Pubitemid 43739439)
4. Aaronson, K.D., Schwartz, J.S., Chen, T.M., Wong, K.L., Goin, J.E. & Mancini, D.M. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95, 2660-2667 (1997). (Pubitemid 27255495)
5. Lee, D.S., Austin, P.C., Rouleau, J.L., Liu, P.P., Naimark, D. & Tu, J.V. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290, 2581-2587 (2003). (Pubitemid 37443288)
6. Brouwers, F.P., Hillege, H.L., van Gilst, W.H. & van Veldhuisen, D.J. Comparing new onset heart failure with reduced ejection fraction and new onset heart failure with preserved ejection fraction: an epidemiologic perspective. Curr. Heart Fail. Rep. 9, 363-368 (2012).
7. Liu, J.W. et al. Recent advances in understanding the biochemical and molecular mechanism of diabetic cardiomyopathy. Biochem. Biophys. Res. Commun. 427, 441-443 (2012).
8. Aroor, A.R., Mandavia, C.H. & Sowers, J.R. Insulin resistance and heart failure: molecular mechanisms. Heart Fail. Clin. 8, 609-617 (2012).
9. Ardehali, H. et al. Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur. J. Heart Fail. 14, 120-129 (2012).
10. Hawkins, N.M. et al. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists. J. Am. Coll. Cardiol. 57, 2127-2138 (2011).
11. Mentz, R.J., Wojdyla, D., Fiuzat, M., Chiswell, K., Fonarow, G.C. & O'Connor, C.M. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am. J. Cardiol. 111, 582-587 (2013).
12. Salpeter, S., Ormiston, T. & Salpeter, E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Coch. Database Syst. Rev. (4), CD003566 (2005) (doi:10.1002/14651858).
13. Damman, K. et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J. Card. Fail. 13, 599-608 (2007). (Pubitemid 47513536)
14. Hillege, H.L. et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102, 203-210 (2000). (Pubitemid 30451778)
15. Yancy, C.W. et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 127(4), e362-425 (2013).
16. Januzzi, J.L. et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur. Heart J. 27, 330-337 (2006). (Pubitemid 43100029)
17. Januzzi, J.L. Jr et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch. Intern. Med. 166, 315-320 (2006). (Pubitemid 43244319)
18. Bettencourt, P., Azevedo, A., Pimenta, J., Friões, F., Ferreira, S. & Ferreira, A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110, 2168-2174 (2004). (Pubitemid 39372496)
19. Sachdeva, A., Horwich, T.B. & Fonarow, G.C. Comparison of usefulness of each of fve predictors of mortality and urgent transplantation in patients with advanced heart failure. Am. J. Cardiol. 106, 830-835 (2010).
20. Tamariz, L., Harzand, A., Palacio, A., Verma, S., Jones, J. & Hare, J. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest. Heart Fail. 17, 25-30 (2011).
21. Cappola, T.P. et al. Allopurinol improves myocardial efciency in patients with idiopathic dilated cardiomyopathy. Circulation 104, 2407-2411 (2001). (Pubitemid 33108372)
22. Gotsman, I., Keren, A., Lotan, C. & Zwas, D.R. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J. Card. Fail. 18, 694-701 (2012).
23. Boueiz, A., Damarla, M. & Hassoun, P.M. Xanthine oxidoreductase in respiratory and cardiovascular disorders. Am. J. Physiol. Lung Cell Mol. Physiol. 294, L830-L840 (2008).
24. Berry, C.E. & Hare, J.M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J. Physiol. (Lond.) 555, 589-606 (2004). (Pubitemid 38404582)
25. Nagarajan, V., Hernandez, A.V. & Tang, W.H. Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart 98, 1778-1786 (2012).
26. Kato, T.S. et al. Risk stratifcation of ambulatory patients with advanced heart failure undergoing evaluation for heart transplantation. J. Heart Lung Transplant. 32, 333-340 (2013).
27. de Groote, P. et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J. Am. Coll. Cardiol. 32, 948-954 (1998). (Pubitemid 28459583)
28. Ghio, S. et al. Prognostic relevance of a non-invasive evaluation of right ventricular function and pulmonary artery pressure in patients with chronic heart failure. Eur. J. Heart Fail. 15, 408-414 (2013).
29. Blumenthal, J.A. et al. Efects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. JAMA 308, 465-474 (2012).
30. Flynn, K.E. et al.; HF-ACTION Investigators. Efects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301, 1451-1459 (2009).
31. O'Connor, C.M. et al.; HF-ACTION Investigators. Efcacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301, 1439-1450 (2009).
32. Packer, M. et al. Efect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N. Engl. J. Med. 335, 1107-1114 (1996). (Pubitemid 26330964)
33. O'Connor, C.M. et al. Efect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am. J. Cardiol. 82, 881-887 (1998). (Pubitemid 28467363)
34. Anand, I.S., Rector, T.S., Kuskowski, M., Thomas, S., Holwerda, N.J. & Cohn, J.N. Efect of baseline and changes in systolic blood pressure over time on the efectiveness of valsartan in the Valsartan Heart Failure Trial. Circ. Heart Fail. 1, 34-42 (2008).
35. Anand, I.S. et al. Infuence of blood pressure on the efectiveness of a fxed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J. Am. Coll. Cardiol. 49, 32-39 (2007). (Pubitemid 46026903)
36. Meredith, P.A. et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. J. Am. Coll. Cardiol. 52, 2000-2007 (2008).
37. Franciosa, J.A., Limas, C.J., Guiha, N.H., Rodriguera, E. & Cohn, J.N. Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet 1, 650-654 (1972).
38. Berkowitz, C., McKeever, L., Croke, R.P., Jacobs, W.R., Loeb, H.S. & Gunnar, R.M. Comparative responses to dobutamine and nitroprusside in patients with chronic low output cardiac failure. Circulation 56, 918-924 (1977). (Pubitemid 8243127)
39. Francis, G.S. Vasodilators and inotropic agents in the treatment of congestive heart failure. Semin. Nephrol. 14, 464-478 (1994). (Pubitemid 24286900)
40. Guiha, N.H., Cohn, J.N., Mikulic, E., Franciosa, J.A. & Limas, C.J. Treatment of refractory heart failure with infusion of nitroprusside. N. Engl. J. Med. 291, 587-592 (1974)
41. Cohn, J.N. & Burke, L.P. Nitroprusside. Ann. Intern. Med. 91, 752-757 (1979). (Pubitemid 10213399)
42. Münzel, T., Daiber, A. & Gori, T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 123, 2132-2144 (2011).
43. Stanich, P.P., Yearsley, M. & Meyer, M.M. Olmesartan-associated Sprue-like enteropathy. J. Clin. Gastroenterol. (2013); e-pub ahead of print 6 June 2013.
44. DeGaetani, M. et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am. J. Gastroenterol. 108, 647-653 (2013).
45. Phillips, C.O., Kashani, A., Ko, D.K., Francis, G. & Krumholz, H.M. Adverse efects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch. Intern. Med. 167, 1930-1936 (2007). (Pubitemid 47606631)
46. Goldhaber, J.I. & Hamilton, M.A. Role of inotropic agents in the treatment of heart failure. Circulation 121, 1655-1660 (2010).
47. Overgaard, C.B. & Dzavík, V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation 118, 1047-1056 (2008).
48. Mikulic, E., Cohn, J.N. & Franciosa, J.A. Comparative hemodynamic efects of inotropic and vasodilator drugs in severe heart failure. Circulation 56, 528-533 (1977). (Pubitemid 8210014)
49. El-Sayed, O.M., Abdelfattah, R.R., Barcelona, R. & Leier, C.V. Dobutamine-induced eosinophilia. Am. J. Cardiol. 93, 1078-1079 (2004). (Pubitemid 38479476)
50. Cufe, M.S. et al.; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287, 1541-1547 (2002).
51. Goldberg, L.I. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol. Rev. 24, 1-29 (1972).
52. Goldberg, L.I. Dopamine-clinical uses of an endogenous catecholamine. N. Engl. J. Med. 291, 707-710 (1974).
53. Goldberg, L.I. Use of sympathomimetic amines in heart failure. Am. J. Cardiol. 22, 177-182 (1968).
54. Bellomo, R., Chapman, M., Finfer, S., Hickling, K. & Myburgh, J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Tr ials Group. Lancet 356, 2139-2143 (2000).
55. Leier, C.V., Heban, P.T., Huss, P., Bush, C.A. & Lewis, R.P. Comparative systemic and regional hemodynamic efects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 58, 466-475 (1978). (Pubitemid 9006974)
56. Pires, L.A., Abraham, W.T., Young, J.B. & Johnson, K.M.; MIRACLE and MIRACLE-ICD Investigators. Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials. Am. Heart J. 151, 837-843 (2006).
57. van Bommel, R.J. et al. Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis. Eur. Heart J. 30, 2470-2477 (2009).
58. Dupont, M. et al. Diferential response to cardiac resynchronization therapy and clinical outcomes according to QRS morphology and QRS duration. J. Am. Coll. Cardiol. 60, 592-598 (2012).
59. European Heart Rhythm Association (EHRA); European Society of Cardiology (ESC); Heart Rhythm Society; Heart Failure Society of America (HFSA); American Society of Echocardiography (ASE); American Heart Association (AHA); European Association of Echocardiography (EAE) of ESC; Heart Failure Association of ESC (HFA); Daubert, J.C. et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace 14, 1236-1286 (2012).
60. Stevenson, W.G. et al. Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. J. Card Fail. 18, 94-106 (2012).
61. Tang, A.S. et al.; Resynchronization-Defbrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N. Engl. J. Med. 363, 2385-2395 (2010).
62. Moss, A.J. et al.; MADIT-CRT Trial Investigators. Cardiac- resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med. 361, 1329-1338 (2009).
63. McMurray, J.J. et al.; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, 1787-1847 (2012).
64. Ochiai, Y. et al. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation 106, I198-I202 (2002).
65. Fitzpatrick, J.R. 3rd et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J. Heart Lung Transplant. 27, 1286-1292 (2008).
66. Matthews, J.C., Koelling, T.M., Pagani, F.D. & Aaronson, K.D. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J. Am. Coll. Cardiol. 51, 2163-2172 (2008). (Pubitemid 351713685)
67. Schulze, P.C. et al. Preoperative assessment of high-risk candidates to predict survival after heart transplantation. Circ. Heart Fail. 6, 527-534 (2013).
68. Efect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007 (1999).
69. Hjalmarson, A. et al. Efects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283, 1295-1302 (2000). (Pubitemid 30129796)
70. Wedel, H. et al.; MERIT-HF Study Group. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am. Heart J. 142, 502-511 (2001). (Pubitemid 32801636)